Right heart catheterization (RHC) is an invasive diagnostic procedure used to measure pressures and blood flow in the right side of the heart and pulmonary arteries. It’s considered the gold standard for diagnosing and assessing pulmonary hypertension and other cardiovascular conditions. This video by the UK Pulmonary Hypertension Association PHA UK with Dr Charlie Elliott, […]
Kristine Sørensen founder of the Global Health Literacy Academy, President of the International Health Literacy Association, and Executive Chair of Health Literacy Europe, brings extensive expertise to the field of health literacy. She currently serves as a visiting lecturer at Bielefeld University in Germany, MCI School of Management in Innsbruck, Austria, and the Centre of
A recent article in Healio news by Isabella Hornick summarises a study titled “Exploring the potential benefits of GLP-1 receptor agonists in pulmonary arterial hypertension: Insights from a large database study”, which was presented at the CHEST Annual Meeting October 19-22, 2025 in Chicago. GLP-1 receptor agonists (Glucagon-Like Peptide-1) are commonly used for diabetes and
A 2025 study published in the Journal of Market Access & Health Policy explores the evolving role of digital health technologies in shaping patient experiences and healthcare delivery. The authors used a mixed-methods approach including a survey of 20 Digital Health Technology developers, and qualitative research with 29 industry representatives from startups to multinational companies
A study on the importance of phenotyping patients with mild pulmonary hypertension was publslhed on the Open Heart journal on October 10, 2025. They found that most patients with mild precapillary pulmonary hypertension have underlying comorbidities rather than early-stage pulmonary arterial hypertension. Stroke volume index emerged as the key independent predictor of prognosis. Survival was
A poster presented by the French Pulmonary Hypertension association HTaPFrance was displayed at the RARE 2025 Congress on October 8, 2025– see photo below with HTaPFrance President Maggy Surace. The poster presents data from a questionnaire that was sent to patients’ families and to the patients. It summarizes the section “Understanding the disease at the
A paper titled “Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study” was recently pubclished in Drugs Real World Outcomes journal. The aim of the authors was to estimate the economic and social burden of pulmonary arterial hypertension (PAH) in Italy, including direct healthcare costs, direct non-healthcare costs, and indirect costs
Menopause affects all women in the pulmonary hypertension community at some stage of their life. A free publication by the Pulmonary Hypertension Association UK answers common questions, shares real experiences, and brings expert advice to support women who are going through the process. Order it here
🫁 National Pulmonary Hypertension Information Day Date: 22 November 2025 | Time: 10:15 – 16:00Location: Congrescentrum De Schakel, Oranjelaan 10, 3862 CX Nijkerk 📍 Venue: Congrescentrum De Schakel, Nijkerk🎈 Theme: “Stronger Together”🎤 Chair: Arieke van Liere An inspiring day full of information, recognition, and connection—especially for people living with pulmonary hypertension, their loved ones, and
A network meta-analysis conducted by researchers at the Cleveland Clinic Abu Dhabi, published in the October 2025 edition of Frontiers in Medicine, compared the efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension (PAH) by synthesizing data from 32 studies, comprising 24 randomised controlled trials, three open-label trials,and five cohort studies, with a cumulative
A recent article by Bharat Desai, an American physician specializing in internal medicine and pulmonary disease, argues that sildenafil could have revolutionized cardiovascular prevention, but was relegated to being an erectile dysfunction drug due to the at-the-time medical environment’s obsession with cholesterol. The Forgotten Origins Sildenafil was originally developed in the early 1990s as a
How Medicine Missed Viagra’s True Potential, MedPage Today, October 15, 2025 Read Post »
A new pre-clinical study shows that stem cell-derived conditioned medium (iPSC-CM)—the liquid remaining after stem cells are cultured—reduces signs of pulmonary arterial hypertension in rat and cell models. In pulmonary arterial hypertension rats treated with daily iPSC-CM infusions, researchers observed reduced blood pressure in the right ventricle, decreased heart enlargement, and thinner pulmonary arterial walls.
On October 11, the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe European Donation Day, the Alliance for Pulmonary Hypertension launched a campaign to to honour donors and their families, to celebrate life after transplant, and to call for greater awareness of the urgent need for organ donation. The six
Introduction: A Mission on Two Wheels On October 11, 2025—European Donation Day, organised yearly by the the Council of Europe—the Alliance for Pulmonary Hypertension launched “Wheels of Hope,” an extraordinary campaign that combines athletic endurance, culinary culture, and life-saving advocacy. Czech chef and athlete Lukáš Jakovec embarked on a 9-month cycling journey from Udine, Italy,
On Monday, 28 September 2025, a State of the Art Session was held at the European Respiratory Society (ERS) Annual Congress 2025 titled: “Pulmonary Hypertension associated with lung diseases: the most burning questions.” The session was chaired by Prof. Dr. Olivier Sitbon, Prof. Dr. David Montani, and Dr. Nesrin Ocal. Leading experts shared the latest
The phase 3 HYPERION trial on sotatercept enrolled 320 adults with newly diagnosed pulmonary arterial hypertension (within 1 year of diagnosis) at intermediate or high risk who were already on double or triple background therapy. Patients were randomized to receive add-on subcutaneous sotatercept or placebo every 21 days. The trial stopped early due to compelling
Despite historical use, the role of anticoagulant therapy in the management of pulmonary arterial hypertension (PAH) remains uncertain, as existing epidemiologic studies have produced conflicting results. The goal of a study whose findings were published in the Journal of the American College of Cardiology on September 30, 2025, was to examine the association between anticoagulant
Traditional risk models for pulmonary arterials hypertension rely heavily on objective measures. While essential, they often miss the patient’s lived experience—symptoms, quality-of-life challenges, and life-context factors that shape treatment decisions. At the symposium organised on 29 September 2025 by MSD at the European Respiratory Society Annual Congress in Amsterdam, on the topic of “The Value
Gossamer Bio has an option to acquire Respira Therapeutics and its inhaled pulmonary arterial hypertension treatment RT234. Gossamer plans to develop RT234 for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), the same two indications for which it is already developing its own inhaled treatment candidate, seralutinib. RT234 is an inhaled formulation
A newly published review in Transplantation Direct explores the growing significance ofextracorporeal photopheresis (ECP), a therapy that modulates immune responses usingpatients’ own treated blood cells. The article, authored by Panagiotis Parsonidis, MSc, and Prof. Thomas Wekerle of the Medical University of Vienna, Austria, highlights extracorporeal photopheresis’s established safety record while pointing to future opportunities for
